RT Journal Article SR Electronic T1 Assessing the Functional Impact of PfRh5 Genetic Diversity on Ex vivo Erythrocyte Invasion Inhibition JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.30.20189175 DO 10.1101/2020.09.30.20189175 A1 Adam J. Moore A1 Khadidiatou Mangou A1 Fatoumata Diallo A1 Seynabou D. Sene A1 Mariama N. Pouye A1 Bacary D. Sadio A1 Ousmane Faye A1 Alassane Mbengue A1 Amy K. Bei YR 2020 UL http://medrxiv.org/content/early/2020/10/02/2020.09.30.20189175.abstract AB The PfRh5-Basigin ligand-receptor interaction is an essential step in the merozoite invasion process and represents an attractive vaccine target. To reveal genotype-phenotype associations between naturally occurring allelic variants of PfRh5 and invasion inhibition, we performed ex vivo invasion inhibition assays with monoclonal antibodies targeting basigin coupled with PfRh5 next-generation amplicon sequencing. We found dose-dependent inhibition of invasion across all isolates tested, and no statistically significant difference in invasion inhibition for any single nucleotide polymorphisms. This study demonstrates that PfRh5 remains highly conserved and functionally essential, even in a highly endemic setting, supporting continued development as a strain-transcendent malaria vaccine target.Competing Interest StatementThe authors have declared no competing interest.Funding StatementG4 group funding (G45267, Malaria Experimental Genetic Approaches & Vaccines) from the Institut Pasteur de Paris and Agence Universitaire de la Francophonie (AUF) to AKB, Yale School of Public Health Start-up funds to AKB, Wilbur Downs Fellowship to AJM, and a Crick African Network Grant CAN/B00002/1 to AM. AKB is supported by an International Research Scientist Development Award (K01 TW010496) from the Fogarty International Center of the National Institutes of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with ethical approval from the National Ethics Committee of Senegal (CNERS) and the Institutional Review Board of the Yale School of Public Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is presented in the paper and is freely available to the public. Sequences have been deposited in Genbank with the following range of identifiers: MW042085-MW042101